Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 3;21(3):352–360. doi: 10.5056/jnm14112

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Korean Society of Neurogastroenterology and Motility

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Effect of SKI3246 on lower gastrointestinal motility in thyrotropin-releasing hormone (TRH) pretreated guinea pigs. (A) Effect of SKI3246 on the cumulative number of egested pellets in guinea pigs pretreated with TRH (control group, n = 7; treatment groups, n = 6). Among TRH-pretreated animals, the cumulative number of egested pellets did not differ between the control group and the group treated with the lowest dose of SKI3246 (150 mg/kg). However, the cumulative number of egested pellets in the groups that received higher doses of SKI3246 was significantly higher than that of the control group (300 mg/kg, P = 0.015 and 600 mg/kg, P = 0.040) by the repeated measures ANOVA test or Greenhouse-Geisser correction method. The group and time differences between subgroups are as follows: (1) Control vs TRH: group and time effect (F = 1.33, P = 0.274 and F = 27.59, P < 0.001), (2) TRH vs TRH + SKI3246 150 mg: group and time effect (F = 1.10, P = 0.319 and F = 15.24, P = 0.001), (3) TRH vs TRH + SKI3246 300 mg: group and time effect (F = 6.17, P = 0.032 and F = 21.96, P < 0.001), (4) TRH vs TRH + SKI3246 600mg: Group and time effect (F=4.27, P=0.066 and F=24.67, P < 0.001), (5) TRH + SKI3246 150 mg vs TRH + SKI3246 300 mg: group and time effect (F = 3.87, P = 0.077 and F = 6.43, P = 0.002), (6) TRH + SKI3246 150 mg vs TRH + SKI3246 600 mg: group and time effect (F = 1.75, P = 0.215 and F = 7.66, P = 0.011), (7) TRH + SKI3246 300 mg vs TRH + SKI3246 600 mg: group and time effect (F = 1.17, P = 0.305 and F = 11.75, P = 0.002). (B) Effect of SKI3246 on the cumulative weight of egested pellets in guinea pigs pretreated with TRH (control group, n = 7; treatment groups, n = 6). Among TRH-pretreated groups, the cumulative weight of egested pellets did not differ between the control group and the group given the lowest dose of SKI3246 (150 mg/kg). However, as compared to control values, the cumulative weight of egested pellets was significantly higher in groups that received SKI3246 at higher doses (300 mg/kg, P = 0.006; and 600 mg/kg, P = 0.023) by the repeated measures ANOVA test or Greenhouse-Geisser correction method. The group and time differences between subgroups are as follows: (1) Control vs TRH: group and time effect (F = 0.78, P = 0.397 and F = 27.80, P < 0.001), (2) TRH vs TRH + SKI3246 150 mg: group and time effect (F = 1.56, P = 0.240 and F = 18.12, P < 0.001), (3) TRH vs TRH + SKI3246 300 mg: group and time effect (F = 5.82, P = 0.037 and F = 22.71, P < 0.001), (4) TRH vs TRH + SKI3246 600 mg: group and time effect (F = 4.30, P = 0.065 and F = 24.37, P < 0.001), (5) TRH + SKI3246 150 mg vs TRH + SKI3246 300 mg: group and time effect (F = 4.15, P = 0.069 and F = 7.86, P = 0.007), (6) TRH + SKI3246 150 mg vs TRH + SKI3246 600 mg: group and time effect (F = 1.86, P = 0.203 and F = 9.13, P < 0.001), (7) TRH + SKI3246 300 mg vs TRH + SKI3246 600 mg: group and time effect (F= 0.847, P = 0.379 and F=14.15, P < 0.001). The error bars indicate standard deviation.